Page last updated: 2024-08-17

carbostyril and Albuminuria

carbostyril has been researched along with Albuminuria in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abram, ME; Arribas, JR; Avihingsanon, A; Benson, P; Bloch, M; Cheng, A; Chetchotisakd, P; Crofoot, G; Custodio, JM; Fordyce, MW; Gathe, J; Gupta, SK; Lichtenstein, K; McCallister, S; Post, FA; Pozniak, A; Ramgopal, M; SenGupta, D; Wei, X1
Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L1
Iizuka, T; Nishikawa, T; Omura, M; Saito, I; Yoshida, S1

Trials

3 trial(s) available for carbostyril and Albuminuria

ArticleYear
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
    Journal of acquired immune deficiency syndromes (1999), 2016, Apr-15, Volume: 71, Issue:5

    Topics: Adult; Albuminuria; Bone Density; Cobicistat; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Proteinuria; Quinolones; Renal Insufficiency; Tenofovir

2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
    Journal of acquired immune deficiency syndromes (1999), 2016, May-01, Volume: 72, Issue:1

    Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir

2016
Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in p
    Arzneimittel-Forschung, 1996, Volume: 46, Issue:9

    Topics: Albuminuria; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Rate; Humans; Male; Middle Aged; Piperidines; Quinolones; Saline Solution, Hypertonic

1996